Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The thienopyridines.

Dieter F Lubbe1, Peter B Berger

  • 1Division of Cardiovascular Diseases, Mayo Clinic, 200 1st Street SW, Rochester, MN 55905, USA.

Journal of Interventional Cardiology
|June 11, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term Deaths After Percutaneous Coronary Intervention Discharge: Prevalence, Risk Factors, and Hospital Risk-Adjusted Mortality.

Journal of the Society for Cardiovascular Angiography & Interventions·2024
Same author

New York Risk Model and Simplified Risk Score for In-Hospital/30-Day Mortality for Percutaneous Coronary Intervention.

The American journal of cardiology·2023
Same author

Ad Hoc Percutaneous Coronary Intervention in Stable Patients With Multivessel or Unprotected Left Main Disease.

JACC. Cardiovascular interventions·2023
Same author

Impact of COVID-19 on percutaneous coronary intervention utilization and mortality in New York.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2023
Same author

Relation of Operator Volume and Access Site to Short-Term Mortality in Radial Versus Femoral Access for Primary Percutaneous Coronary Intervention.

The American journal of cardiology·2022
Same author

Percutaneous Coronary Intervention With and Without Intravascular Ultrasound for Patients With Complex Lesions: Utilization, Mortality, and Target Vessel Revascularization.

Circulation. Cardiovascular interventions·2022
Same journal

Meta-Analysis of Randomized Trials: Efficacy and Safety of Colchicine for Secondary Prevention of Cardiovascular Disease.

Journal of interventional cardiology·2024
Same journal

Effect of Neutrophil-to-Lymphocyte Ratio on Post-TAVR Mortality and Periprocedural Pulmonary Hypertension.

Journal of interventional cardiology·2024
Same journal

Examining the Outcomes of Hybrid Coronary Revascularization in Acute STEMI Patients from 2015 to 2022.

Journal of interventional cardiology·2024
Same journal

Clinical and Laboratory Predictors of Long-Term Outcomes after Catheter Ablation for a Ventricular Electrical Storm.

Journal of interventional cardiology·2024
Same journal

Comparison of Ticagrelor and Clopidogrel in Elective Coronary Stenting: A Double Blind Randomized Clinical Trial.

Journal of interventional cardiology·2024
Same journal

Mitral Valve Transcatheter Edge-to-Edge Repair Volumes and Trends.

Journal of interventional cardiology·2023
See all related articles

Aspirin and clopidogrel combination therapy effectively reduces ischemic events in acute coronary syndromes (ACS). While dual antiplatelet therapy increases bleeding risk, it remains crucial for managing ACS patients, especially after stent implantation.

Area of Science:

  • Cardiology
  • Pharmacology
  • Vascular Medicine

Background:

  • Platelet activation is central to coronary artery disease (CAD) and acute coronary syndromes (ACS).
  • Aspirin, a long-standing antiplatelet, inhibits only thromboxane A2-mediated pathways, leaving other activation routes unaddressed.
  • Therapeutic limitations of aspirin alone necessitate exploring alternative antiplatelet strategies for complex CAD scenarios.

Purpose of the Study:

  • To evaluate the efficacy and safety of dual antiplatelet therapy (DAPT) with aspirin and clopidogrel in managing coronary artery disease, particularly ACS.
  • To compare the outcomes of DAPT with aspirin monotherapy in high-risk cardiovascular conditions.
  • To assess the benefits of novel antiplatelet agents in preventing ischemic events post-intervention.

Main Methods:

Related Experiment Videos

  • Review of clinical trials and therapeutic guidelines concerning antiplatelet agents.
  • Analysis of the mechanisms of action for aspirin and thienopyridines (e.g., clopidogrel).
  • Comparative assessment of DAPT versus aspirin monotherapy in patients with ACS, post-stenting, and post-coronary vascular brachytherapy.

Main Results:

  • Dual antiplatelet therapy with aspirin and clopidogrel significantly reduces ischemic events in ACS patients.
  • Clopidogrel, a thienopyridine, targets adenosine diphosphate (ADP)-mediated platelet activation, offering broader inhibition than aspirin.
  • While DAPT improves outcomes, it is associated with an increased risk of bleeding, particularly in specific patient groups.

Conclusions:

  • Dual antiplatelet therapy (aspirin and clopidogrel) is the standard of care for patients with ACS and following coronary stent implantation.
  • The benefits of DAPT in reducing ischemic events often outweigh the increased bleeding risk in many ACS patients.
  • Further research may focus on optimizing DAPT duration and tailoring therapy to individual patient risk profiles.